Analyst Price Target is $128.43
▲ +108.39% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Apellis Pharmaceuticals in the last 3 months. The average price target is $128.43, with a high forecast of $875.00 and a low forecast of $39.00. The average price target represents a 108.39% upside from the last price of $61.63.
Current Consensus is
The current consensus among 13 polled investment analysts is to buy stock in Apellis Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan. The company was incorporated in 2009 and is based in Waltham, Massachusetts.